BioVie Inc. BIVI
- Market cap
- $13.8M
- P/E
- 0.0×
Follow BIVI
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,750.00 | 150.00 | 263.75 | 220.00 | 436.00 | 132.50 | 113.80 | 10.40 | 1.10 | 0.82 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| 5,625.00 | 3,125.00 | 1,750.00 | 3,454.00 | 4,609.80 | 1,438.00 | 1,139.00 | 331.00 | 25.76 | 3.79 |
High Price
|
|||
| — | — | — | 2 | 2 | 13 | 18 | 14 | 13 | 13 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Gross Margin
|
|||
| (1) | (2) | (2) | (17) | (130) | (26) | (50) | (32) | (18) | (22) |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| (1) | (2) | (2) | (17) | (130) | (26) | (50) | (32) | (18) | (22) |
Net Income
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| (1.25) | (3.75) | (96.23) | (685.00) | (1,482.00) | (106.00) | (155.00) | (73.00) | (12.12) | (3.05) |
Earnings/Sh
|
|||
| (0.87) | (0.81) | (98.49) | (33.03) | (84.30) | (77.01) | (123.93) | (61.84) | (12.88) | (2.63) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| (0.87) | (0.81) | (98.49) | (33.03) | (84.30) | (77.01) | (123.93) | (61.84) | (12.88) | (2.63) |
Free CF/Sh
|
|||
| 1.62 | 0.15 | 83.89 | (436.08) | 40.73 | 14.89 | 47.23 | 34.31 | 12.87 | 1.42 |
Book Value/Sh
|
|||
| 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 7 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| (1) | (1) | (3) | (2) | (10) | (19) | (40) | (28) | (19) | (19) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| (1) | (1) | (3) | (2) | (10) | (19) | (40) | (28) | (19) | (19) |
FCF
|
|||
| (1) | (1) | 0 | (23) | 4 | 15 | 20 | 15 | 18 | 10 |
Working Cap'
|
|||
| 0 | 1 | — | 1 | — | 12 | 14 | — | — | — |
Total Debt
|
|||
| 0 | 1 | 0 | 1 | (5) | (6) | (20) | (24) | (18) | (9) |
Net Debt
|
|||
| 1 | 0 | 2 | (21) | 5 | 4 | 15 | 16 | 19 | 10 |
Sh' Equity
|
|||
| (52.35%) | (107.24%) | (104.97%) | (1,450.13%) | (4,522.36%) | (199.41%) | (182.02%) | (109.45%) | (76.59%) | (123.51%) |
ROA
|
|||
| 0.00% | 0.00% | (87.12%) | 0.00% | (16,017.04%) | 0.00% | 0.00% | 0.00% | (769.48%) | (1,095.00%) |
ROIC
|
|||
| (86.60%) | (383.78%) | (222.37%) | 348.78% | 2,235.46% | (598.19%) | (528.70%) | (214.01%) | (103.78%) | (151.06%) |
ROE
|
|||
BioVie Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NRSN NeuroSense Therapeutics Ltd. | $14.0M | 0.0× | Compare |
| RVLP RVL Pharmaceuticals PLC | $14.1M | 0.0× | Compare |
| LSTA Lisata Therapeutics, Inc. | $13.5M | 0.0× | Compare |
| CLVSQ Clovis Oncology, Inc. | $14.2M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CNSY Cerenome, Inc. | $14.3M | 0.0× | Compare |
| TPST Tempest Therapeutics, Inc. | $14.4M | 0.0× | Compare |
| HIND Vyome Holdings, Inc. | $14.5M | 0.0× | Compare |
| DARE Dare Bioscience, Inc. | $14.5M | 0.0× | Compare |
BioVie Inc. (BIVI) key facts
- BioVie Inc. (BIVI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, BIVI traded at $1.61, a market capitalization of $13.8 million.
- Return on equity was −151.1% and debt-to-equity 0.00.
BioVie Inc. (BIVI) Latest News
15 Sep
BioVie shares fell 9.7% after its Long COVID trial missed statistical significance in the full population. Long COVID trial failure directly triggered 9.7% share drop and signals major setback to BioVie's core pipeline.
BioVie Inc. released topline results from its Phase 2 ADDRESS-LC trial of Bezisterim for neurological symptoms associated with Long COVID. Phase 2 trial data release for lead candidate Bezisterim can materially shift BioVie valuation and development path.
14 Sep
BioVie schedules conference call to review topline data from Phase 2 ADDRESS-LC trial of Bezisterim in Long Covid patients. Phase 2 trial data discussion may moderately affect BioVie's development trajectory and investor views on Bezisterim.
10 Sep
BioVie's lead therapy candidate improved key long COVID symptoms. Positive data on lead candidate for long COVID is likely to drive major gains in valuation and development trajectory.
8 Sep
BioVie advances Parkinson’s Phase 3 development program with FDA engagement. FDA engagement advances Phase 3 Parkinson’s program and signals major regulatory progress for BioVie’s core pipeline.
BioVie updates its Phase 3 development program for a Parkinson’s disease treatment. Phase 3 program update may affect clinical progress and near-term sentiment for the Parkinson’s asset.
31 Aug
BioVie Inc. completed the final patient visit in its Phase 2 Long COVID clinical trial. Final patient visit completion advances the Phase 2 Long COVID study toward data readout and next development steps.
BioVie completed the treatment phase of its ADDRESS-LC trial testing Bezisterim for neurological symptoms linked to Long COVID. Trial phase completion marks incremental progress in BioVie's lead drug program but lacks efficacy data needed to shift company trajectory.
7 Aug
BioVie Inc. is hosting an exclusive live investor webinar focused on the SUNRISE-PD topline results. Webinar disclosure of SUNRISE-PD topline results can drive major shifts in company valuation and investor sentiment.
BioVie Inc. stock declined after release of Phase IIb trial data for its Parkinson's disease treatment. Negative Phase IIb Parkinson's trial data triggered stock decline and signals major setback for BioVie's core drug program.
6 Aug
BioVie Inc. (BIVI) announced positive Phase 2 results for its Parkinson's candidate bezisterim. Positive Phase 2 data for bezisterim signals major pipeline progress that can lift valuation and development trajectory.
BioVie announced topline results from its Phase 2 SUNRISE-PD trial of Bezisterim in early Parkinson’s disease. Phase 2 topline data for a lead Parkinson's candidate can drive major shifts in valuation, development path, and investor sentiment.
5 Aug
BioVie reports positive phase 2 Parkinson's results and plans pivotal phase 3 trial. Positive phase 2 Parkinson's data advances BioVie to phase 3 with strong potential to lift valuation and pipeline progress.
29 May
BioVie completes full enrollment in Long COVID trial. Full enrollment advances Long COVID program to data readout phase.
26 May
BioVie completes enrollment in Long COVID trial as need for treatments grows. Completing trial enrollment advances BioVie's Long COVID program and may moderately affect future performance.
BioVie Inc. completes enrollment in its Phase 2 Long COVID trial. Completing Phase 2 enrollment marks clinical progress that may lift near-term sentiment but lacks immediate revenue or approval effects.
BioVie completes full enrollment of ADDRESS-LC trial testing Bezisterim for neurological symptoms in Long COVID patients. Full enrollment milestone advances Bezisterim development and may influence near-term company valuation.
19 May
BioVie Inc. completed the final patient visit in its Parkinson's drug trial. Final patient visit completion advances Parkinson's trial toward data readout and potential regulatory milestones.
18 May
BioVie Inc. completed its Phase 2 SUNRISE-PD trial in early-stage Parkinson’s disease. Completion of Phase 2 trial advances Parkinson’s drug candidate and may lift valuation and investor interest.
9 May
BioVie CEO shares insights into the company's ongoing long COVID clinical trial. CEO insights on long COVID trial highlight pipeline progress with moderate potential to affect investor sentiment and clinical development trajectory.
4 May
BioVie Inc. (BIVI) advances its long COVID clinical trial, with top-line data expected by summer. Advancing a clinical trial with imminent top-line data signals a major catalyst that could significantly impact stock performance and investor sentiment.
27 Apr
BioVie Inc. (BIVI) will host a virtual KOL event on May 7, 2026, to discuss the Phase 2 study of Bezisterim for Parkinson's Disease ahead of topline data in Q2 2026. KOL event ahead of Phase 2 topline data signals pipeline progress and may moderately boost investor sentiment without immediate transformative effects.
14 Apr
BioVie Inc. (BIVI) abstract on its Parkinson’s drug candidate accepted for presentation at a neurology conference. Abstract acceptance highlights clinical progress in BioVie's core neurodegenerative pipeline and may boost short-term investor sentiment without guaranteeing transformative outcomes.
11 Apr
BioVie CEO explains results of Bezisterim clinical trial for Parkinson's disease in ICYMI update. CEO explanation of Bezisterim Parkinson's trial results significantly affects BioVie's clinical pipeline progress and investor confidence.
9 Apr
BioVie Inc. (BIVI) targets neuroinflammation and insulin resistance as key mechanisms in its Parkinson's disease treatment approach. Targeting neuroinflammation and insulin resistance positions BioVie to advance its Parkinson's pipeline with moderate potential to influence financial performance and competitive standing.
12 Mar
BioVie Inc. (BIVI) to present Parkinson’s study data at AD/PD 2026 conference. Presenting clinical data at a major neurology conference boosts pipeline visibility and investor sentiment but lacks immediate transformative effects due to the distant 2026 timeline.
12 Feb
BioVie Inc. presented its research on bezisterim at the American College of Physicians (ACP) meeting, highlighting the drug's potential in treating conditions related to liver disease. The presentation included data on bezisterim's efficacy and safety profile, aiming to attract interest from healthcare professionals and investors. BioVie is focused on advancing its clinical programs and expanding its market presence. The presentation at a significant medical conference could enhance investor sentiment and support future clinical development efforts.
BioVie Inc. announced that several abstracts have been accepted for presentation at the 2026 American College of Psychiatrists Annual Meeting, highlighting the company's ongoing research and development efforts in the field of psychiatry. The acceptance of abstracts for a prominent conference indicates potential advancements in research that may influence BioVie's competitive positioning.
11 Feb
BioVie Inc. is on the verge of potentially introducing the first new therapy for Parkinson's disease in decades, with its innovative treatment showing promising results in clinical trials. The company aims to address the unmet medical needs of Parkinson's patients, who have limited options for effective therapies. BioVie’s approach focuses on a novel mechanism that could significantly improve patient outcomes and quality of life. As the company moves forward with regulatory processes, the anticipation surrounding its product could reshape the landscape of Parkinson's treatment. The introduction of a new Parkinson's therapy could significantly alter the company's market position and investor sentiment.
8 Jan
BioVie Inc. has completed enrollment in its Phase 2 SUNRISE-PD trial, which focuses on early Parkinson’s disease. The trial aims to evaluate the efficacy and safety of the company's treatment, potentially paving the way for advancements in managing this neurodegenerative condition. This milestone marks a significant step in the company's clinical development efforts. Completion of enrollment in a Phase 2 trial for a neurodegenerative disease could significantly impact BioVie’s future product offerings and market position.